New Options for the Treatment of Hepatocellular Carcinoma

Incidence and Impact of HCC

Today's Program: A Focus on Unresectable Disease

Patient Case #1: Front-Line

SHARP Trial: Front-Line Sorafenib Efficacy

SHARP Trial: AEs

Lenvatinib vs Sorafenib Efficacy: REFLECT

Lenvatinib Is Non-Inferior to Sorafenib in First-Line Advanced HCC

Lenvatinib vs Sorafenib: AEs

Patient Case #1 (cont)

Pharmacist's Role in Maintaining Compliance With Oral Medications

Managing AEs: Diarrhea

Lenvatinib Dosing Considerations

Patient Case #1 Conclusion

Patient Case #2

CELESTIAL Trial: Cabozantinib

Cabozantinib Toxicity Consistent With Other TKIs

REACH Trials: Ramucirumab

AEs With Ramucirumab

CheckMate 040 Trial: Nivolumab

CheckMate 040 Trial: AEs

KEYNOTE-224 Trial: Pembrolizumab

Considerations for Second-Line Treatment Selection

Selecting Optimal Second-Line Treatment

Patient Case #2 (cont)

Managing irAEs: Rash

Patient Case #2 Conclusion

Concluding Remarks

Abbreviations

Abbreviations (cont)